We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.
TODAY'S HIGH
1927
TODAY'S LOW
1889
52 WEEK HIGH
3014.95
52 WEEK LOW
1560.1
% of Shares Held by
All Insider
47.43%
% of Shares Held by
Institutions
31.48%
% of Float Held by
Institutions
59.89%
Number of Institutions
Holding Shares
133
MARKET CAP
45855.70 Cr.
ETERPRISE VALUE
93042 Cr.
NO. OF SHARES
23.86 Cr.
BOOK VALUE
1486.993
DIV. YIELD
33%
DEBT
55702.95 Cr.
GROSS PROFIT
11760.79 Cr.
CASH
9864.37 Cr.
REVENUE
15205.56 Cr.
REVENUE/SHARE
637.156
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 1158.72 Cr. | -1505.62 Cr. | 1898.33 Cr. | -364.15 Cr. |
| Change To Liabilities | 144.42 Cr. | 183.95 Cr. | 171.26 Cr. | 152.50 Cr. |
| Total cashflows from Investing Activities | -2226.18 Cr. | -2772.25 Cr. | 7468.69 Cr. | -826.51 Cr. |
| Net Borrowings | -6166.12 Cr. | -648.56 Cr. | -14915.40 Cr. | 12272.12 Cr. |
| Total Cash from Financing Activities | -6987.97 Cr. | 2071.58 Cr. | -13018.56 Cr. | 10751.82 Cr. |
| Other Liabilities | 5807.54 Cr. | 3132.27 Cr. | 4707.33 Cr. | -15774.52 Cr. |
| Total Assets | 199.67 Cr. | 199.67 Cr. | 3480.95 Cr. | 6.87 Cr. |
| Net Income | 1923.11 Cr. | 1332.34 Cr. | 24.03 Cr. | 1467.06 Cr. |
| Change in Cash | 699.98 Cr. | 2970.07 Cr. | 1988.34 Cr. | -1679.38 Cr. |
| Effect of Exchange Rate | -2.05 Cr. | -4.22 Cr. | 21.87 Cr. | 12.18 Cr. |
| Total Cash from Operating Activities | 8749.59 Cr. | 3664.54 Cr. | 7516.34 Cr. | -11611.16 Cr. |
| Depreciation | 665.78 Cr. | 543.37 Cr. | 570.07 Cr. | 427.29 Cr. |
| Other Cashflows from Investing Activities | 283.48 Cr. | 208.34 Cr. | 253.51 Cr. | 250.53 Cr. |
| Dividends Paid | -797.59 Cr. | -315.75 Cr. | -556.73 Cr. | -448.23 Cr. |
| Change to Inventory | -253.18 Cr. | -231.24 Cr. | -304.42 Cr. | -69 Cr. |
| Change to Account Receivables | -56.08 Cr. | -238.57 Cr. | -159.02 Cr. | -105.96 Cr. |
| Other Cashflows from Financing Activities | -223.93 Cr. | 2960.89 Cr. | -1027.38 Cr. | -1078.94 Cr. |
| Change to Net Income | 206.74 Cr. | 1064.20 Cr. | 2399.64 Cr. | 972.11 Cr. |
| Capital Expenditures | -958.42 Cr. | -595.18 Cr. | -470.66 Cr. | -691.90 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 2509.56 Cr. | 3455.77 Cr. | 1407.12 Cr. | 2541.84 Cr. |
| Minority Interest | 1347.78 Cr. | 1121 Cr. | 1121 Cr. | 9.03 Cr. |
| Net Income | 6504.55 Cr. | 7089.45 Cr. | 6205.21 Cr. | 7100.05 Cr. |
| Selling General Administrative | 2135.01 Cr. | 1800.37 Cr. | 1772.93 Cr. | 1707.45 Cr. |
| Gross Profit | 12182.42 Cr. | 10857.39 Cr. | 11547.45 Cr. | 10528.52 Cr. |
| Ebit | 6504.55 Cr. | 7089.45 Cr. | 6205.21 Cr. | 7100.05 Cr. |
| Operating Income | 6504.55 Cr. | 7089.45 Cr. | 6205.21 Cr. | 7100.05 Cr. |
| Other Operating Expenses | 2877.08 Cr. | 1406.67 Cr. | 3047.69 Cr. | 1303.18 Cr. |
| Interest Expense | -4479.87 Cr. | -4088.53 Cr. | -5062.51 Cr. | -3994.06 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 510.79 Cr. | 2042.91 Cr. | 1960.43 Cr. | 852.22 Cr. |
| Total Revenue | 14713.41 Cr. | 12977.16 Cr. | 13400.84 Cr. | 12192.20 Cr. |
| Total Operating Expenses | 8208.86 Cr. | 5887.71 Cr. | 7195.63 Cr. | 5092.15 Cr. |
| Cost of Revenue | 2530.99 Cr. | 2119.77 Cr. | 1853.39 Cr. | 1663.68 Cr. |
| Total Other Income Expense Net | -3994.99 Cr. | -3633.68 Cr. | -4798.09 Cr. | -4558.21 Cr. |
| Discontinued Operations | 0 | 0 | 574.45 Cr. | -225.53 Cr. |
| Net Income from Continuous Ops. | 1998.77 Cr. | 1412.86 Cr. | -553.31 Cr. | 1689.62 Cr. |
| Net Income Applicable to Common Shares | 1923.11 Cr. | 1332.34 Cr. | 24.03 Cr. | 1467.06 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 3377.75 Cr. | 2757.01 Cr. | 2912.84 Cr. | 3094.46 Cr. |
| Capital Surplus | 0 | 12946.74 Cr. | 9697.25 Cr. | 2944.50 Cr. |
| Total Liabilities | 63036 Cr. | 41979.90 Cr. | 44336.99 Cr. | 58380.15 Cr. |
| Stock Holder Equity | 35489.13 Cr. | 34017.96 Cr. | 30571.59 Cr. | 27224.27 Cr. |
| Minority Interest | 1347.78 Cr. | 1121 Cr. | 0 | 9.03 Cr. |
| Other Liabilities | 5242.74 Cr. | 512.82 Cr. | 569.83 Cr. | 736.96 Cr. |
| Total Assets | 99872.91 Cr. | 77118.86 Cr. | 74908.58 Cr. | 85613.45 Cr. |
| Common Stock | 47.73 Cr. | 45.11 Cr. | 45.11 Cr. | 36.89 Cr. |
| Retained Earnings | 0 | 18764.82 Cr. | 18062.48 Cr. | 17379.35 Cr. |
| Other Liabilities | 394.21 Cr. | 395.50 Cr. | 213.54 Cr. | 263.42 Cr. |
| Good Will | 1294.70 Cr. | 1114.28 Cr. | 1139.07 Cr. | 5939.45 Cr. |
| Treasury Stock | 35441.40 Cr. | 2261.29 Cr. | 2766.75 Cr. | 6863.53 Cr. |
| Other Assets | 44599.32 Cr. | 31549.95 Cr. | 35370.52 Cr. | 38362.27 Cr. |
| Cash | 7184.75 Cr. | 5719.01 Cr. | 4340.94 Cr. | 811.73 Cr. |
| Current Liabilities | 18699.88 Cr. | 13347.25 Cr. | 23673 Cr. | 31083.66 Cr. |
| Long Term Asset Charges | 1367.91 Cr. | 937.24 Cr. | 2372.32 Cr. | 4068.45 Cr. |
| Short Long Term Debt | 11672.64 Cr. | 7909.95 Cr. | 13798.38 Cr. | 13425.22 Cr. |
| Other Stockholder Equity | 35441.40 Cr. | 2261.29 Cr. | 2766.75 Cr. | 6863.53 Cr. |
| Property Plant Equipment | 4313.74 Cr. | 3327.10 Cr. | 2880.67 Cr. | 2656.78 Cr. |
| Total Cur. Assets | 24312.47 Cr. | 19867.42 Cr. | 16113.08 Cr. | 12261.02 Cr. |
| Long Term Investments | 21974.93 Cr. | 18503.10 Cr. | 16492.40 Cr. | 23299.47 Cr. |
| Net Tangible Assets | 30816.68 Cr. | 30146.67 Cr. | 26519.68 Cr. | 18190.36 Cr. |
| Short Term Investments | 2881.59 Cr. | 1709.93 Cr. | 2723.27 Cr. | 1634.36 Cr. |
| Net Receivables | 10599.27 Cr. | 6640.66 Cr. | 5444.20 Cr. | 6719.82 Cr. |
| Long Term Debt | 43778.36 Cr. | 28096.76 Cr. | 20306.25 Cr. | 27033.07 Cr. |
| Inventory | 1533.01 Cr. | 1299.23 Cr. | 1061.17 Cr. | 831.33 Cr. |
| Accounts Payable | 1696.09 Cr. | 1178.39 Cr. | 989.83 Cr. | 960.87 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account